• Explore /
  • Poster
  • / Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC).

Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Jorge Garcia

Jorge A. Garcia

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Jorge A. Garcia , Robert Dreicer , Allan J. Pantuck , Naomi B. Haas , Ulka N. Vaishampayan , Drew W. Rasco , Allison Janine Tyler , Niranjan Sathyanarayana Rao , Penelope J. Bristow , Sanjeeva Reddy , Louis J. Denis , Anthony W. Tolcher

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Prostate Cancer,Urothelial Carcinoma,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02349139

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 240)

DOI

10.1200/JCO.2017.35.6_suppl.240

Abstract #

240

Poster Bd #

C8

Abstract Disclosures

Similar Posters

First Author: Jorge A. Garcia

First Author: Ulka N. Vaishampayan

First Author: Edwin M. Posadas

First Author: Daniel Petrylak